Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Abstract
Molecular testing has become a mandatory component of the non-small cell lung cancer (NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the analysis of ALK, ROS1, RET and NTRK translocations have already been incorporated in the NSCLC diagnostic standards, and the inhibitors of these kinases are in routine clinical use. There are emerging biomarkers, e.g., KRAS G12C substitutions and HER2 activating alterations, which are likely to enter NSCLC guidelines upon the approval of the corresponding drugs. In addition to genetic examination, NSCLCs are usually subjected to the analysis of PD-L1 protein expression in order to direct the use of immune checkpoint inhibitors. Comprehensive NSCLC testing for multiple predictive markers requires the analysis of distinct biological molecules (DNA, RNA, proteins) and, therefore, the involvement of different analytical platforms (PCR, DNA sequencing, immunohistochemistry, FISH). There are ongoing efforts aimed at the integration of multiple NSCLC molecular assays into a single diagnostic pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,184
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review
Arbour, K. C., & Riely, G. J. (2019) · JAMA · doi:10.1001/jama.2019.11058 · Cited by 1,060
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 828
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Kinsey, C. G., Camolotto, S. A., Boespflug, A. M., Guillen, K. P., Foth, M., Truong, A., Schuman, S. S., Shea, J. E., Seipp, M. T., Yap, J. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0367-9 · Cited by 634
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Harrison, P. T., Vyse, S., & Huang, P. H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.015 · Cited by 615
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K., Rosen, E. Y., Frosina, D., Jungbluth, A. A., Zehir, A., Benayed, R., Drilon, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0324-7 · Cited by 546
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 511
Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0912 · Cited by 505
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
Camidge, D. R., Dziadziuszko, R., Peters, S., Mok, T., Noe, J., Nowicka, M., Gadgeel, S. M., Cheema, P., Pavlakis, N., de Marinis, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.007 · Cited by 490
Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 486
Benayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Abandoning the Notion of Non-Small Cell Lung Cancer
Relli, V., Trerotola, M., Guerra, E., & Alberti, S. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.012 · Cited by 461
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Ruiz-Cordero, R., & Devine, W. P. (2020) · Surgical Pathology Clinics · doi:10.1016/j.path.2019.11.002 · Cited by 448
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz204 · Cited by 372
Rekhtman, N., Paik, P. K., Arcila, M. E., Tafe, L. J., Oxnard, G. R., Moreira, A. L., Travis, W. D., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2109 · Cited by 364
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 360
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2294 · Cited by 349
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz288 · Cited by 338
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.107 · Cited by 332
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor, J. N., Boumber, Y., & Borghaei, H. (2020) · Cancer · doi:10.1002/cncr.32468 · Cited by 329
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 318
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W., Paz-Ares, L., & Schmid-Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 311
Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237863 · Cited by 310
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S., Tu, H.-Y., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 288
Sholl, L. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 283
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Yang, J. C.-H., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.126 · Cited by 274
Isomoto, K., Haratani, K., Hayashi, H., Shimizu, S., Tomida, S., Niwa, T., Yokoyama, T., Fukuda, Y., Chiba, Y., Kato, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2027 · Cited by 248
Peters, S., Stahel, R., Bubendorf, L., Bonomi, P., Villegas, A., Kowalski, D. M., Baik, C. S., Isla, D., Carpeno, J. D. C., Garrido, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 236
Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C., Gao, G., Ng, T. L., Tu, M. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 207
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 207
Zhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 205
Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw436 · Cited by 200
Smeltzer, M. P., Wynes, M. W., Lantuejoul, S., Soo, R., Ramalingam, S. S., Varella-Garcia, M., Meadows Taylor, M., Richeimer, K., Wood, K., Howell, K. E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.002 · Cited by 192
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
Mazieres, J., Cropet, C., Montané, L., Barlesi, F., Souquet, P. J., Quantin, X., Dubos-Arvis, C., Otto, J., Favier, L., Avrillon, V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.022 · Cited by 189
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Gautschi, O., Milia, J., Cabarrou, B., Bluthgen, M.-V., Besse, B., Smit, E. F., Wolf, J., Peters, S., Früh, M., Koeberle, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000625 · Cited by 186
Mechanisms of acquired tumor drug resistance
Aleksakhina, S. N., Kashyap, A., & Imyanitov, E. N. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188310 · Cited by 177
Self-citationHorn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Leal, T. A., Du, L., Hernandez, J., Huang, V., Blumenschein, G. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.003 · Cited by 171
Molecular Diagnostics in Clinical Oncology
Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 166
Proto, C., Ferrara, R., Signorelli, D., Russo, G. L., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.004 · Cited by 164
Duruisseaux, M., Besse, B., Cadranel, J., Pérol, M., Mennecier, B., Bigay-Game, L., Descourt, R., Dansin, E., Audigier-Valette, C., Moreau, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15746 · Cited by 158
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
Davies, K. D., Lomboy, A., Lawrence, C. A., Yourshaw, M., Bocsi, G. T., Camidge, D. R., & Aisner, D. L. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.020 · Cited by 156
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 154
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Gregg, J. P., Li, T., & Yoneda, K. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.14 · Cited by 140
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 132
Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130
Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 129
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
Hida, T., Velcheti, V., Reckamp, K. L., Nokihara, H., Sachdev, P., Kubota, T., Nakada, T., Dutcus, C. E., Ren, M., & Tamura, T. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.011 · Cited by 128
Hofman, P. M., Badoual, C., Henderson, F., Berland, L., Hamila, M., Long-Mira, É., Lassalle, S., Roussel, H., Hofman, V., Tartour, É., et al. (2019) · Cancers · doi:10.3390/cancers11030283 · Cited by 127
A worldwide trend of increasing primary adenocarcinoma of the lung
Nakamura, H., & Saji, H. (2013) · Surgery Today · doi:10.1007/s00595-013-0636-z · Cited by 125
Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
Phallen, J. A., Leal, A., Woodward, B. D., Forde, P. M., Naidoo, J., Marrone, K. A., Brahmer, J. R., Fiksel, J., Medina, J. E., Cristiano, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1082 · Cited by 117
McVeigh, T. P., & Kerin, M. J. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s109847 · Cited by 115
Nadal, E., Massutí, B., Dómine, M., García‐Campelo, R., Cobo, M., & Felip, E. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02310-2 · Cited by 114
Negrao, M. V., Lam, V. K., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 112
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Drilon, A., Fu, S., Patel, M. R., Fakih, M., Wang, D., Olszanski, A. J., Morgensztern, D., Liu, S. V., Cho, B. C., Bazhenova, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0839 · Cited by 111
Childress, M. A., Himmelberg, S. M., Chen, H., Deng, W., Davies, M. A., & Lovly, C. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0171 · Cited by 108
Friedlaender, A., Banna, G. L., Malapelle, U., Pisapia, P., & Addeo, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00166 · Cited by 106
Volckmar, A., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., de Oliveira, C. M. M., Rempel, E., Buchhalter, I., Brandt, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32133 · Cited by 105
Schüler, M., Berardi, R., Lim, W., de Jonge, M. J. A., Bauer, T. M., Azaro, A., Gottfried, M., Han, J., Lee, D. H., Wollner, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.293 · Cited by 105
Hendriks, L. E. L., Rouleau, É., & Besse, B. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.22 · Cited by 104
Garrido, P., Conde, E., de Castro, J., Gómez‐Román, J., Felip, E., Pijuán, L., Isla, D., Sanz, J., Paz-Ares, L. G., & López‐Ríos, F. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02218-4 · Cited by 103
Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91
The force of HER2 – A druggable target in NSCLC?
Jebbink, M., Langen, A. J. D., Boelens, M. C., Monkhorst, K., & Smit, E. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101996 · Cited by 87
Li, W., Liu, Y., Li, W., Chen, L., & Ying, J. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.023 · Cited by 86
Novel ALK fusion partners in lung cancer
Iyevleva, A. G., Раскин, Г. А., Tiurin, V. I., Соколенко, А. П., Mitiushkina, N. V., Алексахина, С. Н., Garifullina, A. R., Strelkova, T. N., Merkulov, V. O., Ivantsov, A. O., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.028 · Cited by 83
Self-citationNovel chemotherapy regimens for advanced lung cancer: have we reached a plateau?
Baxevanos, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.04 · Cited by 82
Lee, J. W., Zhang, Y., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 80
Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases
Warth, A., Körner, S., Penzel, R., Muley, T., Dienemann, H., Schirmacher, P., Doeberitz, M. V. K., Weichert, W., & Kloor, M. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1892-7 · Cited by 77
Jänne, P. A., Smith, I., McWalter, G., Mann, H., Dougherty, B., Walker, J., Orr, M. C. M., Hodgson, D. R., Shaw, A. T., Pereira, J. R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.215 · Cited by 76
Conde, E., Hernández, S., Martínez, R., Angulo, B., de Castro, J., Collazo-Lorduy, A., Jiménez, B., Muriel, A., Mate, J. L., Morán, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.005 · Cited by 76
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Salgia, R., Sattler, M., Scheele, J., Stroh, C., & Felip, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102022 · Cited by 76
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 72
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
Lantuéjoul, S., Damotte, D., Hofman, V., & Adam, J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.103 · Cited by 69
Norris, R. P., Dew, R., Sharp, L., Greystoke, A., Rice, S. J. C., Johnell, K., & Todd, A. (2020) · BMC Medicine · doi:10.1186/s12916-020-01753-0 · Cited by 69
Terlizzi, M., Colarusso, C., Pinto, A., & Sorrentino, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.005 · Cited by 68
Is tissue still the issue in detecting molecular alterations in lung cancer?
Liam, C. K., Mallawathantri, S., & Fong, K. M. (2020) · Respirology · doi:10.1111/resp.13823 · Cited by 67
Resistance to molecularly targeted therapy in non-small-cell lung cancer
Asao, T., Takahashi, F., & Takahashi, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.001 · Cited by 65
Thorne-Nuzzo, T., Williams, C., Catallini, A., Clements, J., Singh, S., Amberson, J. B., Dickinson, K., Gatalica, Z., Ho, S. N., Loftin, I. R., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.020 · Cited by 63
Pacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 61
Morris, T. A., Khoo, C., & Solomon, B. (2019) · Drugs · doi:10.1007/s40265-019-01164-3 · Cited by 59
Cheung, C. C., Barnes, P. J., Bigras, G., Boerner, S. L., BUTANY, J. W., Calabrese, F., Couture, C., Deschênes, J., El-Zimaity, H. M. T., Fischer, G., et al. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000800 · Cited by 58
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
Rosas, G., Ruiz, R., Araujo, J. M., Pinto, J. A., & Mas, L. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.006 · Cited by 53
Mitiushkina, N. V., Iyevleva, A. G., Полторацкий, А. Н., Ivantsov, A. O., Togo, A. V., Polyakov, I. S., Орлов, С. В., Matsko, D. E., Новик, В. И., & Имянитов, Е. Н. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21281 · Cited by 51
Self-citationKRAS: Reasons for optimism in lung cancer
Lindsay, C. R., Jamal-Hanjani, M., Forster, M., & Blackhall, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 51
High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
Moiseyenko, V. M., Procenko, S. A., Levchenko, E., As, B., Moiseenko, F. V., Iyevleva, A. G., Mitiushkina, N. V., Togo, A. V., Semionov, I. I., Ivantsov, A. O., et al. (2010) · Onkologie · doi:10.1159/000302729 · Cited by 48
Self-citationMolecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC
Tan, A. C., Seet, A. O. L., Lai, G. G. Y., Lim, T. H., Lim, A. S. T., Tan, G. S., Takano, A. M., Tai, D. W.-M., Tan, T. J., Lam, J. Y. C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.011 · Cited by 48
Vendrell, J. A., Mazières, J., Senal, R., Rouquette, I., Quantin, X., Pujol, J.-L., Roch, B., Bouidioua, A., Godreuil, S., Coyaud, É., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2683 · Cited by 44
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Mhanna, L., Guibert, N. M., Milia, J., & Mazières, J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0652-3 · Cited by 44
Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer
Имянитов, Е. Н., Демидова, И. А., Gordiev, M., Филипенко, М. Л., Kekeeva, T. V., Moliaka, Y. K., Анатольевна, Г. П., Kozhemyako, V. B., Vodolazhskiy, D. I., Sergeyeva, L. A., et al. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0213-4 · Cited by 43
Self-citationHaynes, B. C., Blidner, R., Cardwell, R. D., Zeigler, R., Gokul, S., Thibert, J. R., Chen, L., Fujimoto, J., Papadimitrakopoulou, V. A., Wistuba, I. I., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.012 · Cited by 43
The genomic landscape of nonsmall cell lung carcinoma in never smokers
Boeckx, B., Shahi, R. B., Smeets, D., Brakeleer, S. D., Decoster, L., Brussel, T. V., Galdermans, D., Vercauter, P., Decoster, L., Alexander, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32797 · Cited by 42
Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay
Guo, Q., Wang, L., Yu, W., Qiao, L., Zhao, M., Hu, X., Sun, Y., Ni, S., Xu, Y., & Lou, J. (2019) · Journal of Cancer · doi:10.7150/jca.31326 · Cited by 38
Spagnuolo, A., Maione, P., & Gridelli, C. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1527902 · Cited by 34
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
Malapelle, U., Rossi, G., Pisapia, P., Barberis, M. C. P., Buttitta, F., Castiglione, F., Cecere, F. L., Grimaldi, A. M., Iaccarino, A., Marchetti, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103118 · Cited by 32
Genomic Testing in Lung Cancer: Past, Present, and Future
Mascaux, C., Tsao, M., & Hirsch, F. R. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7019 · Cited by 30
Li, H., Wang, C., Wang, Z., Hu, Y., Zhang, G., Zhang, M., Zheng, X., Zhang, X., Yang, J., Ma, Z., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.001 · Cited by 30
Li, X., Zhang, L., Jiang, D., Wang, Y., Zang, A., Ding, C., Zhao, M., Su, W., Zhang, Y., Zhong, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3064 · Cited by 28
HER2: defining a Neu target in non-small-cell lung cancer
Ekman, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz043 · Cited by 27
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
Canale, M., Pasini, L., Bronte, G., Delmonte, A., Cravero, P., Crinò, L., & Ulivi, P. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.15 · Cited by 27
Coleman, N., Woolf, D., Welsh, L. C., McDonald, F., MacMahon, S., Yousaf, N., & Popat, S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.006 · Cited by 24
Opportunities of circulating tumor DNA in lung cancer
Wu, T., Hsiue, E. H.-C., & Yang, J. C. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.002 · Cited by 21
Lavdovskaia, E. D., Iyevleva, A. G., Соколенко, А. П., Mitiushkina, N. V., Преображенская, Е. В., Tiurin, V. I., Ivantsov, A. O., Валерьевич, Б. И., Stelmakh, L. V., Moiseenko, F. V., et al. (2018) · Oncology Research and Treatment · doi:10.1159/000491441 · Cited by 18
Self-citationHeeke, S., Benzaquen, J., Hofman, V., Long-Mira, É., Lespinet‐Fabre, V., Bordone, O., Marquette, C., Delingette, H., Ilié, M., & Hofman, P. M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.013 · Cited by 18
Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment
Iyevleva, A. G., Mitiushkina, N. V., Karaseva, N. A., Орлов, С. В., Volodina, L. N., Kulikova, Y. E., Lozhkina, A. M., Ivantsov, A. O., Tiurin, V. I., Togo, A. V., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000106 · Cited by 17
Self-citationMitiushkina, N. V., Kholmatov, M. M., Tiurin, V. I., Romanko, A. A., Yatsuk, O. S., Sokolova, T. N., Ivantsov, A. O., Kuligina, E. S., Stepanov, I. A., Belyaev, А. М., et al. (2019) · Biochimie · doi:10.1016/j.biochi.2019.08.014 · Cited by 15
Rajadurai, P., Cheah, P., How, S. H., Liam, C. K., Annuar, M. A. A., Omar, N., Othman, N., Marzuki, N. M., Pang, Y. K., Bustamam, R. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.005 · Cited by 13
Mitiushkina, N. V., Kholmatov, M. M., Venina, A. R., Tiurin, V. I., Yanus, G. A., Николаевна, С. Т., Yatsuk, O. S., Zaitseva, O. A., Ivantsov, A. O., Kuligina, E. S., et al. (2018) · Neoplasma · doi:10.4149/neo_2018_171225n843 · Cited by 12
Gao, W., Wu, J., Chen, X., Lin, L., Fei, X., Shen, K., & Huang, O. (2019) · Journal of Cancer · doi:10.7150/jca.29337 · Cited by 12
Thunnissen, E., Lissenberg-Witte, B. I., van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sørensen, J. B., Mellemgaard, A., Dingemans, A. C., Speel, E. M., Langen, A. J. D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.023 · Cited by 12
Orlov, S., Urtenova, M. A., Sviridenko, M. A., Nesterov, D. V., Sokolova, T. N., & Имянитов, Е. Н. (2020) · Case Reports in Oncology · doi:10.1159/000509241 · Cited by 12
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
Имянитов, Е. Н., Ivantsov, A. O., & Tsimafeyeu, I. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.549198 · Cited by 3
Cited by
Advances and challenges in the treatment of lung cancer
Li, Y., Yan, B., & He, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115891 · Cited by 462
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
Metadata
- Authors
- Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 157
- Pages
- 103194
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W3110833960
- Cited by
- 526
- References
- 140
- FWCI
- 33.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.